Android app Apple app link

AD/PD 2025: Cerevance's Solengepras falls short of primary endpoint in ASCEND trial

By Yahoo! Finance   |   1 month ago
AD/PD 2025: Cerevance's Solengepras falls short of primary endpoint in ASCEND trial

At the AD/PD 2025 Conference, Cerevance revealed that solengepras didn't meet its primary endpoint in the Phase II ASCEND trial for early Parkinson's disease. The drug showed potential benefits in non-motor symptoms despite missing statistical significance.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.